Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henk J Out

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Reproductive Biomedicine Online|January 18, 2006
Recombinant follicle-stimulating hormone: gold standard or not?Henk J Out
International Surgery|April 18, 2007
Optimizing the gonadotrophin dose regimenHenk J Out, Laurie E Thomas
BMJ (Clinical Research Ed.)|September 8, 2011
Tackling conflicts of interest. Industry tie may be benchmark of qualityMarlies van Lent, Henk J Out
BMC Medical Research Methodology|October 2, 2013
Recommendations for a uniform assessment of publication bias related to funding sourceMarlies van Lent, John Overbeke, Henk J Out
Human Fertility (Cambridge, England)|April 10, 2002
The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory dataHenk J Out, Bernadette M J L Mannaerts
American Journal of Obstetrics and Gynecology|July 3, 2021
Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently neededEdith Roset Bahmanyar, Henk J Out, Marcel van Duin
BMC Medical Ethics|December 11, 2014
Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical reviewMarlies van Lent, Gerard A Rongen, Henk J Out
Human Reproduction (Oxford, England)|December 23, 2003
A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproductionHenk J Out, Anthony Rutherford, Richard Fleming, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Reproductive Biomedicine Online|January 18, 2006
Recombinant follicle-stimulating hormone: gold standard or not?Henk J Out
International Surgery|April 18, 2007
Optimizing the gonadotrophin dose regimenHenk J Out, Laurie E Thomas
BMJ (Clinical Research Ed.)|September 8, 2011
Tackling conflicts of interest. Industry tie may be benchmark of qualityMarlies van Lent, Henk J Out
BMC Medical Research Methodology|October 2, 2013
Recommendations for a uniform assessment of publication bias related to funding sourceMarlies van Lent, John Overbeke, Henk J Out
Human Fertility (Cambridge, England)|April 10, 2002
The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory dataHenk J Out, Bernadette M J L Mannaerts
American Journal of Obstetrics and Gynecology|July 3, 2021
Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently neededEdith Roset Bahmanyar, Henk J Out, Marcel van Duin
BMC Medical Ethics|December 11, 2014
Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical reviewMarlies van Lent, Gerard A Rongen, Henk J Out
Human Reproduction (Oxford, England)|December 23, 2003
A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproductionHenk J Out, Anthony Rutherford, Richard Fleming, et al.
Pageof 1